Komori
Other Disclosures4263SUSMED,Inc.Information and Communications, Services and Others

Publication of Results of Specified Clinical Research on a Therapeutic App for Premenstrual Syndrome and Premenstrual Dysphoric Disorder

The results of specified clinical research on a therapeutic app for PMS and PMDD were published on jRCT after a statistically significant improvement in the primary endpoint was confirmed compared with the control app. The results are also scheduled to be presented orally at an academic conference in the future.

Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Therapeutic app for PMS and PMDD
Applicable field (uses covered by this announcement)

Treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)

Contract DateSeptember 2023 (agreement between ASKA Pharmaceutical and SUSMED,Inc. concerning research and development and sales)
What the company reported numerically
Quantitative Effects

Statistically significant improvement in the primary endpoint versus the control app (specific figures: Not disclosed)

Relationship between the counterparty and the company
SUSMED,Inc.4263
Relationship with the Company

ASKA Pharmaceutical and SUSMED conducted specified clinical research jointly with Professor Ogawa Mariko (小川真理子) of Fukushima Medical University. In September 2023, ASKA Pharmaceutical and SUSMED entered into an agreement covering the research and development and sale of therapeutic apps in the field of obstetrics and gynecology.

CounterpartyPublic University Corporation Fukushima Medical University, Fukushima Center for Children and Women's Health Support

The medical support center of the public university corporation to which Professor Ogawa Mariko (小川真理子) belongs. Location, representative, capital and year established: Not disclosed.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Clinical Research Submission and Disclosure System (jRCT: Japan Registry of Clinical Trials)

Announced details
ItemDetails
Names of Products / Services CoveredTherapeutic app for PMS and PMDD
CounterpartyPublic University Corporation Fukushima Medical University, Fukushima Center for Children and Women's Health Support
Counterparty overviewThe medical support center of the public university corporation to which Professor Ogawa Mariko (小川真理子) belongs. Location, representative, capital and year established: Not disclosed.
Relationship with the CompanyASKA Pharmaceutical and SUSMED conducted specified clinical research jointly with Professor Ogawa Mariko (小川真理子) of Fukushima Medical University. In September 2023, ASKA Pharmaceutical and SUSMED entered into an agreement covering the research and development and sale of therapeutic apps in the field of obstetrics and gynecology.
Contract DateSeptember 2023 (agreement between ASKA Pharmaceutical and SUSMED,Inc. concerning research and development and sales)
Applicable areaTreatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)
Quantitative EffectsStatistically significant improvement in the primary endpoint versus the control app (specific figures: Not disclosed)
SourceClinical Research Submission and Disclosure System (jRCT: Japan Registry of Clinical Trials)
Items this document does not state (10)
Contract ValueOffering priceLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the aim is to provide a new treatment option for PMS and PMDD and contribute to the advancement of medicine.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Publication of Results of Specified Clinical Research on a Therapeutic App for Premenstrual Syndrome and Premenstrual Dysphoric Disorder | SUSMED,Inc. (4263) timely disclosure | Komori